Archive: 2015

 

 

Rex Bionics Positive Interim Data from RAPPER II

27 November 2015: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from an interim analysis of its RAPPER II clinical trial. RAPPER II (Robot-Assisted PhysiotherapExercises with REX) is a trial to evaluate the safety and feasibility of a set of customised exercises performed in a REX. This first phase of RAPPER II entailed a single visit to the REX clinic, consisting of a walk test and a set of exercises, with immediate post-experience follow-up.  

Read more about Rex Bionics Positive Interim Data from RAPPER II

Nexvet – Animal Health Symposium

Overview of the symposium:

1, The Animal health industry and opportunities for innovation.

2. An overview of Nexvet:

Details of the successful NV-01 pivotal study

Next steps for Nexvet’s development programs...

Read more about Nexvet – Animal Health Symposium

Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015.

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK.

Read more about Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK.

Read more about Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK

AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a Phase I clinical study. 

Read more about AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs. 

Read more about Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis

Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015

Jeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015.

Read more about Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015

Avita Medical Announces Positive Interim Clinical Study Results On Restoration of Pigment in Burn Scars at Clinical Cosmetic & Reconstructive Expo

Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is pleased to report the presentation of results obtained with the use of ReCell® Spray-On Skin® at the recent Clinical Cosmetic & Reconstructive Expo held in London, England 11-12 October, 2013.

Read more about Avita Medical Announces Positive Interim Clinical Study Results On Restoration of Pigment in Burn Scars at Clinical Cosmetic & Reconstructive Expo

Nexvet Initiates Pilot Field Study of NV-02 for Feline Osteoarthritis Pain

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats.

Read more about Nexvet Initiates Pilot Field Study of NV-02 for Feline Osteoarthritis Pain

Avita Medical Announces AUD$ 10M Equity Financing

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. 09 3 per share.

Read more about Avita Medical Announces AUD$ 10M Equity Financing

1 2 3 4 5 ... 8